Tags

Type your tag names separated by a space and hit enter

A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
Curr Med Res Opin. 2019 08; 35(8):1355-1364.CM

Abstract

Objective: Baloxavir marboxil (baloxavir) is the first cap-dependent endonuclease inhibitor being studied for the treatment of influenza in single oral dosing regimen. This network meta-analysis (NMA) evaluated the efficacy and safety of baloxavir compared to other antivirals for influenza in otherwise healthy patients. Methods: A systematic literature review was performed on 14 November 2016 in Medline, Embase, CENTRAL, and ICHUSHI to identify randomized controlled trials assessing antivirals for influenza. A NMA including 22 trials was performed to compare the efficacy and safety of baloxavir with other antivirals. Results: The time to alleviation of all symptoms was significantly shorter for baloxavir compared to zanamivir (difference in median time 19.96 h; 95% CrI [3.23, 39.07]). The time to cessation of viral shedding was significantly shorter for baloxavir than zanamivir and oseltamivir (47.00 h; 95% CrI [28.18, 73.86] and 56.03 h [33.74, 87.86], respectively). The mean decline in virus titer from baseline to 24 h was significantly greater for baloxavir than for the other drugs. Other differences in efficacy outcomes were not significant. No significant differences were found between baloxavir and the other antivirals for safety, except total drug-related adverse events where baloxavir demonstrated a decrease compared to oseltamivir and laninamivir. Conclusions: The NMA suggests that baloxavir demonstrated better or similar efficacy results compared to other antivirals with a comparable safety profile. Baloxavir led to a significant decrease in viral titer versus zanamivir, oseltamivir and peramivir and decreased viral shedding versus zanamivir and oseltamivir.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Taieb V
a Creativ-Ceutical , London , UK.
Ikeoka H
b Shionogi & Co. Ltd , Osaka , Japan.
Ma FF
c Creativ-Ceutical , Paris , France.
Borkowska K
d Creativ-Ceutical , Krakow , Poland.
Aballéa S
c Creativ-Ceutical , Paris , France.
Tone K
e Shionogi Limited , London , UK.
Hirotsu N
f Hirotsu Clinic , Kanagawa , Japan.

MeSH

Antiviral AgentsDibenzothiepinsEnzyme InhibitorsHumansInfluenza, HumanMorpholinesNetwork Meta-AnalysisNeuraminidaseOxazinesPyridinesPyridonesThiepinsTriazines

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

30810054

Citation

Taieb, Vanessa, et al. "A Network Meta-analysis of the Efficacy and Safety of Baloxavir Marboxil Versus Neuraminidase Inhibitors for the Treatment of Influenza in Otherwise Healthy Patients." Current Medical Research and Opinion, vol. 35, no. 8, 2019, pp. 1355-1364.
Taieb V, Ikeoka H, Ma FF, et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019;35(8):1355-1364.
Taieb, V., Ikeoka, H., Ma, F. F., Borkowska, K., Aballéa, S., Tone, K., & Hirotsu, N. (2019). A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Current Medical Research and Opinion, 35(8), 1355-1364. https://doi.org/10.1080/03007995.2019.1584505
Taieb V, et al. A Network Meta-analysis of the Efficacy and Safety of Baloxavir Marboxil Versus Neuraminidase Inhibitors for the Treatment of Influenza in Otherwise Healthy Patients. Curr Med Res Opin. 2019;35(8):1355-1364. PubMed PMID: 30810054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. AU - Taieb,Vanessa, AU - Ikeoka,Hidetoshi, AU - Ma,Fang-Fang, AU - Borkowska,Katarzyna, AU - Aballéa,Samuel, AU - Tone,Keiko, AU - Hirotsu,Nobuo, Y1 - 2019/04/01/ PY - 2019/2/28/pubmed PY - 2020/6/10/medline PY - 2019/2/28/entrez KW - Baloxavir KW - influenza KW - network meta-analysis KW - otherwise healthy patients SP - 1355 EP - 1364 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 35 IS - 8 N2 - Objective: Baloxavir marboxil (baloxavir) is the first cap-dependent endonuclease inhibitor being studied for the treatment of influenza in single oral dosing regimen. This network meta-analysis (NMA) evaluated the efficacy and safety of baloxavir compared to other antivirals for influenza in otherwise healthy patients. Methods: A systematic literature review was performed on 14 November 2016 in Medline, Embase, CENTRAL, and ICHUSHI to identify randomized controlled trials assessing antivirals for influenza. A NMA including 22 trials was performed to compare the efficacy and safety of baloxavir with other antivirals. Results: The time to alleviation of all symptoms was significantly shorter for baloxavir compared to zanamivir (difference in median time 19.96 h; 95% CrI [3.23, 39.07]). The time to cessation of viral shedding was significantly shorter for baloxavir than zanamivir and oseltamivir (47.00 h; 95% CrI [28.18, 73.86] and 56.03 h [33.74, 87.86], respectively). The mean decline in virus titer from baseline to 24 h was significantly greater for baloxavir than for the other drugs. Other differences in efficacy outcomes were not significant. No significant differences were found between baloxavir and the other antivirals for safety, except total drug-related adverse events where baloxavir demonstrated a decrease compared to oseltamivir and laninamivir. Conclusions: The NMA suggests that baloxavir demonstrated better or similar efficacy results compared to other antivirals with a comparable safety profile. Baloxavir led to a significant decrease in viral titer versus zanamivir, oseltamivir and peramivir and decreased viral shedding versus zanamivir and oseltamivir. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/30810054/A_network_meta_analysis_of_the_efficacy_and_safety_of_baloxavir_marboxil_versus_neuraminidase_inhibitors_for_the_treatment_of_influenza_in_otherwise_healthy_patients_ DB - PRIME DP - Unbound Medicine ER -